The lancet oncology
-
The lancet oncology · Nov 2014
ReviewLocal treatments for metastases of renal cell carcinoma: a systematic review.
Local treatment of metastases such as metastasectomy or radiotherapy remains controversial in the treatment of metastatic renal cell carcinoma. To investigate the benefits and harms of various local treatments, we did a systematic review of all types of comparative studies on local treatment of metastases from renal cell carcinoma in any organ. ⋯ Nevertheless, the available evidence was marred by high risks of bias and confounding across all studies. Although the findings presented here should be interpreted with caution, they and the identified gaps in knowledge should provide guidance for clinicians and researchers, and directions for further research.
-
The lancet oncology · Nov 2014
Randomized Controlled TrialDetection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers.
Low-dose CT screening is recommended for individuals at high risk of developing lung cancer. However, CT screening does not detect all lung cancers: some might be missed at screening, and others can develop in the interval between screens. The NELSON trial is a randomised trial to assess the effect of screening with increasing screening intervals on lung cancer mortality. In this prespecified analysis, we aimed to assess screening test performance, and the epidemiological, radiological, and clinical characteristics of interval cancers in NELSON trial participants assigned to the screening group. ⋯ Zorgonderzoek Nederland Medische Wetenschappen and Koningin Wilhelmina Fonds.
-
The lancet oncology · Nov 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Standard treatments for indolent non-Hodgkin lymphomas are often toxic, and most patients ultimately relapse. Lenalidomide, an immunomodulatory agent, is effective as monotherapy for relapsed indolent non-Hodgkin lymphoma. We assessed the efficacy and safety of lenalidomide plus rituximab in patients with untreated, advanced stage indolent non-Hodgkin lymphoma. ⋯ Celgene Corporation and Richard Spencer Lewis Memorial Foundation and Cancer Center Support Grant.